| Market Research A to Z | Company Profiles A to Z | Register | Contact Us |
| +44 (0) 203 086 8600 Call us on |
Market |
Healthcare and Medical |
Report Type |
Market Research |
Country |
Vietnam |
Published |
3 March 2010 |
Number of Pages |
86 |
Download |
|
Immediate |
|
Publisher |
Business Monitor International |
File Format |
- |
Vietnam's pharmaceutical market was valued at around VND27,265bn (US$1.53bn) in 2009. Over the next five years, we forecast that the market should grow at a compound annual growth rate (CAGR) of 15.8% in local currency terms to reach a value of VND56,706bn (US$3.29bn) in 2014. Our long-range forecast is for the market to reach VND89,509bn (US$6.07bn) in 2019, equating to a CAGR of 12.6%. Our forecast for GDP-beating drug market growth underlines our view that there is considerable scope for increased pharmaceutical consumption in a country where per-capita drug expenditure is currently just US$17.
Access to healthcare remains a key concern in a country where per-capita GDP is a little over US$1,000. In January 2010, Vietnam introduced a new Law on Health Insurance that would see around 90% of patients subject to some form of co-payment, raising concerns that access to healthcare for people on low incomes may be restricted. The legislation states that certain patients – ethnic minorities, welfare recipients and people who contributed to the revolution – must pay 5% of medical services costing more that VND97,500 (US$5.28). Students, employees and others not obliged to buy health insurance will have to pay 20% of healthcare costs out-of-pocket.
In our Asia Pacific Pharmaceutical Business Environment Ratings for Q210, Vietnam was ranked 13th of the 15 markets surveyed. The country's pharmaceutical market is growing rapidly, but low per-capita spending limits potential returns. Meanwhile, an uncertain pricing environment creates the largest risks for pharmaceutical firms operating in Vietnam. Some pharmacies registered a 10-30% increase in drug prices in a period of less than two weeks in December 2009, despite warnings from the Vietnam Drug Administration (VDA) against outlets not to raise prices.
There have been a number of positive developments in Vietnam's pharmaceutical industry in recent months. The Hanoi University of Pharmacy is to produce Fludon H1 (arbidol) in 2010 to combat H1N1 influenza. Once manufacturing of arbidol in Vietnam has been scaled up, the medicine is expected to be more than four times cheaper than Tamiflu, the first-line treatment for swine flu. Meanwhile, the country's biotechnology sector has continued to demonstrate the ability to develop new vaccines with an announcement by Company for Vaccine and Biological Production No. 1 (Vabiotech) that commercial batches of a vaccine against H1N1 influenza were ready for testing by the National Institute for Control of Vaccine and Biologicals (NICVB).
|
All posts are pre-moderated and must obey the house rules. |
|
Healthcare and Medical Company Profiles contain up to date financial, strategic, operational, SWOT analysis and product information on the activities of thousands of healthcare and medical companies.
Do you manage an industry specific website or blog? Are you looking to monetise your web traffic further? Are you a B2B website?
Why not offer your visitors industry specific strategic market reports and company profiles? Our Affiliate Program enables you to provide quality content on your website and to earn money from passing on visitors to our website. If a sale is made from your visitor, you earn commission (a fixed percentage of the price of a product).
Cannot find what you need? We can tailor a report for you. Complete the Custom Research Form and we will provide a quote.